Literature DB >> 8982769

Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone.

T K Li1, B S Fox.   

Abstract

Cholera toxin (CT) is a powerful immunomodulator with strong adjuvant activity. Much of this activity is retained by the binding component alone, cholera toxin B subunit (CTB). Little is known about the mechanism of the immunomodulatory activity of CTB. In this study, both CT and CTB were found to dramatically enhance IL-4 production from a T cell clone stimulated with antigen and the B cell hybridoma LB as antigen-presenting cell (APC). Enhancement of cytokine production was seen following pretreatment of the APC with CT or CTB, while pretreatment of the T cells had no effect. Furthermore, stimulatory activity on the APC was stable to fixation with paraformaldehyde, demonstrating that the activity was mediated by a surface molecule on the APC. CT-pretreated APC also enhanced IL-4 production from anti-CD3 mAb-stimulated T cells, indicating that CT was providing a co-stimulatory signal. CT treatment of LB cells did not alter the expression of class II MHC molecules, CTLA-4 counter-receptors, LFA-1 or ICAM-1. When mAb were raised against the CT-pretreated APC, the only antibodies that were found to inhibit IL-4 production were those specific for CTB itself. The antibodies blocked even when the CT or CTB were already bound to the APC, arguing that co-stimulation was provided by a direct interaction with CTB. Blocking experiments suggested that APC-associated CTB molecules are interacting with non-GM1 receptors on the T cells. This novel finding of CTB-mediated T-B interaction provides one of the first potential mechanisms for the adjuvant activity of CTB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982769     DOI: 10.1093/intimm/8.12.1849

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Autoantigens plus interleukin-10 suppress diabetes autoimmunity.

Authors:  Béla Dénes; István Fodor; William H R Langridge
Journal:  Diabetes Technol Ther       Date:  2010-08       Impact factor: 6.118

2.  Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin.

Authors:  F Sultan; L L Jin; M G Jobling; R K Holmes; S L Stanley
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

3.  Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts--oral administration protects against development of insulitis in non-obese diabetic mice.

Authors:  Tracey Ruhlman; Raheleh Ahangari; Andrew Devine; Mohtahsem Samsam; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2007-05-09       Impact factor: 9.803

4.  Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.

Authors:  D G Millar; T R Hirst; D P Snider
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.

Authors:  M Marinaro; A Di Tommaso; S Uzzau; A Fasano; M T De Magistris
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  A single point mutation within the coding sequence of cholera toxin B subunit will increase its expression yield.

Authors:  Bita Bakhshi; Mina Boustanshenas; Masoud Ghorbani
Journal:  Iran Biomed J       Date:  2014-07

7.  A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against Acinetobacter baumannii.

Authors:  Peng Sun; Xin Li; Chao Pan; Zhicheng Liu; Jun Wu; Hengliang Wang; Li Zhu
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.